Senolytic Effects on Cognition, Mobility, and Biomarkers in Older Adults with MCI and Slow Gait: A Pilot Study
2024

Effects of Senolytic Drugs on Older Adults with Cognitive Impairment

Sample size: 12 publication Evidence: low

Author Information

Author(s): Millar Courtney, Iloputaife Ike, Baldyga Kathryn, Norling Amani, Boulougoura Afroditi, Vichos Theodoros, Tchkonia Tamara, Kirkland Jim

Primary Institution: Hebrew SeniorLife

Hypothesis

Does treatment with senolytic drugs improve cognition and mobility in older adults with mild cognitive impairment and slow gait?

Conclusion

The study suggests that intermittent treatment with senolytic drugs may improve cognition and reduce certain biomarkers in older adults with slow gait and mild cognitive impairment.

Supporting Evidence

  • MoCA scores improved significantly by 2 points in participants with the lowest baseline scores.
  • Mean percent change in TNF-α decreased following treatment.
  • Reduction in TNF-α was significantly correlated with increases in MoCA scores.

Takeaway

This study looked at whether two drugs could help older people who walk slowly and have some memory problems. It found some signs that the drugs might help, but more research is needed.

Methodology

Participants took two senolytic drugs for two days every two weeks over 12 weeks, and changes in cognition, mobility, and biomarkers were measured.

Limitations

The data are preliminary and must be interpreted with caution.

Participant Demographics

Older adults with mild cognitive impairment and slow gait.

Statistical Information

P-Value

0.04

Confidence Interval

95%CI: -0.7, 2.7; 95%CI: -0.003, 0.066; 95%CI: 0.1, 4.0; 95%CI: -13.0, 7.1

Statistical Significance

p=0.04

Digital Object Identifier (DOI)

10.1093/geroni/igae098.3709

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication